StreetInsider.com News Articles

Lucid Capital Markets Starts Microbot Medical (MBOT) at Buy

Wed, 03 Jun 2026 07:09:11 -0400

(Updated - June 3, 2026 7:09 AM EDT)

Lucid Capital Markets analyst Alex Nowak initiates coverage on Microbot Medical (NASDAQ: MBOT) with a Buy rating and a price target of $4.00.

The analyst comments "A Blue Ocean with No Real Competition: Endovascular intervention is a roughly 5-6M- procedure U.S. market (about 3M coronary, 2M-2.5M peripheral, and the remaining neurovascular), serviced by a concentrated base of ~15K physicians across ~8K facilities representing at least $40B in annual spend, yet

Lucid Capital Markets Starts Microbot Medical (MBOT) at Buy

Wed, 03 Jun 2026 07:09:11 -0400

(Updated - June 3, 2026 7:09 AM EDT)

Lucid Capital Markets analyst Alex Nowak initiates coverage on Microbot Medical (NASDAQ: MBOT) with a Buy rating and a price target of $4.00.

Lucid Capital Markets Starts Microbot Medical (MBOT) at Buy

Wed, 03 Jun 2026 07:09:11 -0400

(Updated - June 3, 2026 7:09 AM EDT)

Lucid Capital Markets analyst Alex Nowak initiates coverage on Microbot Medical (NASDAQ: MBOT) with a Buy rating and a price target of $4.00.

Lucid Capital Markets Starts Microbot Medical (MBOT) at Buy

Wed, 03 Jun 2026 07:09:11 -0400

(Updated - June 3, 2026 7:09 AM EDT)

Lucid Capital Markets analyst Alex Nowak initiates coverage on Microbot Medical (NASDAQ: MBOT) with a Buy rating and a price target of $4.00.

Microbot Medical gains first North Carolina customer for robotic system

Tue, 02 Jun 2026 08:30:54 -0400

Microbot Medical Inc. (NASDAQ: MBOT) announced it secured its first customer in North Carolina for its LIBERTY Endovascular Robotic System, according to a company press release. The healthcare system operates a multi-hospital network across the state and represents the company's expansion into the Southeast and Mid-Atlantic regions.

The Massachusetts-based medical device company described the customer as a leading academic center, marking what it called the first adoption in the Southeast and Mid-Atlantic region. The announcement follows the full market release of the LIBERTY system, which the company describes as a single-use, remotely operated robotic solution for endovascular procedures.

"It's exciting to see

Form 8-K Microbot Medical Inc. For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588142.html

Form 8-K Microbot Medical Inc. For: Jun 02

Tue, 02 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26588142.html

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Tue, 02 Jun 2026 08:30:00 -0400

A leading academic center becomes the first user in the Southeast, Mid-Atlantic region

HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it has secured its first North Carolina-based customer, becoming the latest healthcare system to adopt the LIBERTY System, demonstrating a broadening geographic penetration from the Southeast, Mid-Atlantic and Northeast U.S. The Company’s latest account delivers state of the art patient care through a multi-hospital network that encompasses the entire state and joins a growing roster of health systems that

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Tue, 02 Jun 2026 08:30:00 -0400

A leading academic center becomes the first user in the Southeast, Mid-Atlantic region

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Tue, 02 Jun 2026 08:30:00 -0400

A leading academic center becomes the first user in the Southeast, Mid-Atlantic region

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Tue, 02 Jun 2026 08:30:00 -0400

A leading academic center becomes the first user in the Southeast, Mid-Atlantic region

Microbot Medical receives first international approval for robotic system

Tue, 26 May 2026 08:32:17 -0400

Microbot Medical Inc. (NASDAQ: MBOT) received regulatory approval from Israel's Ministry of Health to market its LIBERTY Endovascular Robotic System, marking the first international clearance for the device outside the United States.

The approval from the AMAR Division allows the company to commercialize the robotic system in Israel and obtain a Free Sale Certificate to support regulatory submissions in additional markets. Microbot continues pursuing CE Mark certification with completion targeted by the end of 2026 for European Union market entry.

The LIBERTY system received FDA clearance and has been adopted by hospitals across six U.S. states including Georgia, Florida, New York, Massachusetts,

Form 8-K Microbot Medical Inc. For: May 26